Biotechnology plays a significant role in shaping the future of medicine and the pharmaceutical industry. Thanks to continuous advanced research, pharmaceutical companies can benefit from solutions tailored to the needs of the patient. One such biotechnological solution is liposome carriers, cGMP production and RNA synthesis, which affects the quality of life and the natural environment. What is the encapsulation of therapeutic molecules, which include DNA, RNA, and proteins?
- How does the genetic platform work?
- Processes taking place on the delivery platform
- Work undertaken on the production platform
How does the genetic platform work?
The task of the genetic platform is to provide support in optimising the conditions of RNA synthesis and in the event of various problems related to this process. We are talking about technical and scientific support. At this stage, it is important to provide the highest quality synthesis of ribonucleic acids. Only then can a high level of process repeatability be achieved, which translates into time savings and the possibility of scaling production. Safety is also important, i.e. maintaining the product at the highest level of purity and impeccability. You can find more information about it on https://www.syvento.com.
Processes taking place on the delivery platform
SyVento’s encapsulated drug development focuses on lipid-based formulations, including liposomes, solid lipid particles, nanostructured lipid carriers, lipid nanoparticles, and self-emulsifying drug delivery system SEDDS.
Product development begins with goal identification, preclinical testing related to formulation, and changes to the formulation as needed. Then a group of candidates is selected for testing and a batch of drug is produced to be used in clinical trials. The clinical trials themselves are designed to help determine whether the drug can be introduced into large-scale production.
Work undertaken on the production platform
The production process must be fully compliant with cGMP standards. Constant control and maintaining the highest production quality are also important. SyVento uses an extensive equipment base, thanks to which it can fill up to 2-3 thousand vials per hour. It is possible to perform both small and very large production batches.
Cooperation with SyVento is not only the above-mentioned services. It is also assistance in product development, starting from the earliest clinical phases. It is also assistance in introducing the product to the market. It is important to maintain the highest quality standards and use the potential of the manufactured drug, as well as its commercialisation.
